These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36252106)

  • 1. Suppression and Replacement Gene Therapy for
    Bains S; Zhou W; Dotzler SM; Martinez K; Kim CJ; Tester DJ; Ye D; Ackerman MJ
    Circ Genom Precis Med; 2022 Dec; 15(6):e003719. PubMed ID: 36252106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promise and Potential Peril With Lumacaftor for the Trafficking Defective Type 2 Long-QT Syndrome-Causative Variants, p.G604S, p.N633S, and p.R685P, Using Patient-Specific Re-Engineered Cardiomyocytes.
    O'Hare BJ; John Kim CS; Hamrick SK; Ye D; Tester DJ; Ackerman MJ
    Circ Genom Precis Med; 2020 Oct; 13(5):466-475. PubMed ID: 32940533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression-Replacement
    Dotzler SM; Kim CSJ; Gendron WAC; Zhou W; Ye D; Bos JM; Tester DJ; Barry MA; Ackerman MJ
    Circulation; 2021 Apr; 143(14):1411-1425. PubMed ID: 33504163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGK1 inhibition attenuated the action potential duration in patient- and genotype-specific re-engineered heart cells with congenital long QT syndrome.
    Kim M; Das S; Tester DJ; Pradhananga S; Hamrick SK; Gao X; Srinivasan D; Sager PT; Ackerman MJ
    Heart Rhythm O2; 2023 Apr; 4(4):268-274. PubMed ID: 37124559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome sequencing in a genetically elusive multigenerational long QT syndrome pedigree identifies a novel LQT2-causative deeply intronic KCNH2 variant.
    Tobert KE; Tester DJ; Zhou W; Haglund-Turnquist CM; Giudicessi JR; Ackerman MJ
    Heart Rhythm; 2022 Jun; 19(6):998-1007. PubMed ID: 35144019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico assessment of the effects of quinidine, disopyramide and E-4031 on short QT syndrome variant 1 in the human ventricles.
    Luo C; Wang K; Zhang H
    PLoS One; 2017; 12(6):e0179515. PubMed ID: 28632743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Efficacy of Mexiletine for Long QT Syndrome Type 2: Evidence From Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes, Transgenic Rabbits, and Patients.
    Crotti L; Neves R; Dagradi F; Musu G; Giannetti F; Bos JM; Barbieri M; Cerea P; Giovenzana FLF; Torchio M; Mura M; Gnecchi M; Conte G; Auricchio A; Sala L; Odening KE; Ackerman MJ; Schwartz PJ
    Circulation; 2024 Jun; ():. PubMed ID: 38939955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elucidation of
    Zhou W; Ye D; Tester DJ; Bains S; Giudicessi JR; Haglund-Turnquist CM; Orland KM; January CT; Eckhardt LL; Maginot KR; Ackerman MJ
    Circ Genom Precis Med; 2023 Apr; 16(2):e003726. PubMed ID: 37071726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-Specific and Gene-Corrected Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Short QT Syndrome.
    Guo F; Sun Y; Wang X; Wang H; Wang J; Gong T; Chen X; Zhang P; Su L; Fu G; Su J; Yang S; Lai R; Jiang C; Liang P
    Circ Res; 2019 Jan; 124(1):66-78. PubMed ID: 30582453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Injectable contraceptive Depo-Provera induces erratic beating patterns in patient-specific induced pluripotent stem cell-derived cardiomyocytes with long QT syndrome type 2.
    Pinsky AM; Gao X; Bains S; Kim CJ; Louradour J; Odening KE; Tester DJ; Giudicessi JR; Ackerman MJ
    Heart Rhythm; 2023 Jun; 20(6):910-917. PubMed ID: 36889623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and characterization of an induced pluripotent stem cell (iPSC) line (NUIGi003-A) from a long QT syndrome type 2 (LQT2) patient harbouring the KCNH2 c.2464G>A pathogenic variant.
    Ge N; Liu M; Krawczyk J; McInerney V; Ward D; Shen S; O'Brien T; Prendiville T
    Stem Cell Res; 2020 Dec; 49():101997. PubMed ID: 33002718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long QT Syndrome Type 2: Emerging Strategies for Correcting Class 2
    Ono M; Burgess DE; Schroder EA; Elayi CS; Anderson CL; January CT; Sun B; Immadisetty K; Kekenes-Huskey PM; Delisle BP
    Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32759882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome Editing of Induced Pluripotent Stem Cells to Decipher Cardiac Channelopathy Variant.
    Garg P; Oikonomopoulos A; Chen H; Li Y; Lam CK; Sallam K; Perez M; Lux RL; Sanguinetti MC; Wu JC
    J Am Coll Cardiol; 2018 Jul; 72(1):62-75. PubMed ID: 29957233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of three heterozygous KCNH2 mutation-carrying human induced pluripotent stem cell lines for modeling LQT2 syndrome.
    Mondéjar-Parreño G; Jahng JWS; Belbachir N; Wu BC; Zhang X; Perez MV; Badhwar N; Wu JC
    Stem Cell Res; 2021 Jul; 54():102402. PubMed ID: 34051449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tbx20 controls the expression of the KCNH2 gene and of hERG channels.
    Caballero R; Utrilla RG; Amorós I; Matamoros M; Pérez-Hernández M; Tinaquero D; Alfayate S; Nieto-Marín P; Guerrero-Serna G; Liu QH; Ramos-Mondragón R; Ponce-Balbuena D; Herron T; Campbell KF; Filgueiras-Rama D; Peinado R; López-Sendón JL; Jalife J; Delpón E; Tamargo J
    Proc Natl Acad Sci U S A; 2017 Jan; 114(3):E416-E425. PubMed ID: 28049825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional Invalidation of Putative Sudden Infant Death Syndrome-Associated Variants in the
    Smith JL; Tester DJ; Hall AR; Burgess DE; Hsu CC; Elayi SC; Anderson CL; January CT; Luo JZ; Hartzel DN; Mirshahi UL; Murray MF; Mirshahi T; Ackerman MJ; Delisle BP
    Circ Arrhythm Electrophysiol; 2018 May; 11(5):e005859. PubMed ID: 29752375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients With Long-QT Syndrome Caused by Impaired
    Hyltén-Cavallius L; Iepsen EW; Wewer Albrechtsen NJ; Svendstrup M; Lubberding AF; Hartmann B; Jespersen T; Linneberg A; Christiansen M; Vestergaard H; Pedersen O; Holst JJ; Kanters JK; Hansen T; Torekov SS
    Circulation; 2017 May; 135(18):1705-1719. PubMed ID: 28235848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic short-QT syndrome 1 rabbits mimic the human disease phenotype with QT/action potential duration shortening in the atria and ventricles and increased ventricular tachycardia/ventricular fibrillation inducibility.
    Odening KE; Bodi I; Franke G; Rieke R; Ryan de Medeiros A; Perez-Feliz S; Fürniss H; Mettke L; Michaelides K; Lang CN; Steinfurt J; Pantulu ND; Ziupa D; Menza M; Zehender M; Bugger H; Peyronnet R; Behrends JC; Doleschall Z; Zur Hausen A; Bode C; Jolivet G; Brunner M
    Eur Heart J; 2019 Mar; 40(10):842-853. PubMed ID: 30496390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of the β-adrenoceptor blockers carvedilol and metoprolol on SQT1- and SQT2-mutant channels.
    Bodi I; Franke G; Pantulu ND; Wu K; Perez-Feliz S; Bode C; Zehender M; zur Hausen A; Brunner M; Odening KE
    J Cardiovasc Electrophysiol; 2013 Oct; 24(10):1163-71. PubMed ID: 23718892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional characterization and identification of a therapeutic for a novel SCN5A-F1760C variant causing type 3 long QT syndrome refractory to all guideline-directed therapies.
    Stutzman MJ; Gao X; Kim M; Ye D; Zhou W; Tester DJ; Giudicessi JR; Shannon K; Ackerman MJ
    Heart Rhythm; 2023 May; 20(5):709-717. PubMed ID: 36731785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.